Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors

Oncogene

Volumn 24, Issue 31, 2005, Pages 4993-4999

  Zhu, Hongbo ^a   Zhang, Lidong ^b   Dong, Fengqin ^b   Guo, Wei ^b   Wu, Shuhong ^b   Teraishi, Fuminori ^b   Davis, John J ^b,c   Chiao, Paul J ^b   Fang, Bingliang ^b,c  

^a ZHEJIANG UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Apoptosis; Bik; Bortezomib; Proteasome inhibitor; PS 341

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CALPASTATIN; CASPASE 3; CASPASE 9; CYTOCHROME C; I KAPPA B ALPHA; PROTEASOME INHIBITOR; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; EPITHELIUM CELL; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; RELAPSE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BORONIC ACIDS; CELL LINE; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; HUMANS; KIDNEY; MEMBRANE PROTEINS; NF-KAPPA B; OVARIAN NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 22344442683     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1208683     Document Type: Article

References (21)

1. Adams J. (2002a). Oncologist, 7, 9-16.
2. Adams J. (2002b). Curr. Opin. Oncol., 14, 628-634.
3. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S and Elliott PJ. (1999). Cancer Res., 59, 2615-2622.
4. Boyd JM, Gallo GJ, Elangovan B, Houghton AB, Malstrom S, Avery BJ, Ebb RG, Subramanian T, Chittenden T, Lutz RJ and Chinnadurai, G. (1995). Oncogene, 11, 1921-1928.
5. Gillissen B, Essmann F, Graupner V, Starck L, Radetzki S, Dorken B, Schulze-Osthoff K and Daniel PT. (2003). EMBO J., 22, 3580-3590.
6. Goldstein JC, Waterhouse NJ, Juin P, Evan GI and Green DR. (2000). Nat. Cell Biol., 2, 156-162.
7. Hur J, Chesnes J, Coser KR, Lee RS, Geck P, Isselbacher KJ and Shioda T. (2004). Proc. Natl. Acad. Sci. USA, 101, 2351-2356.
8. Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA, Curley SA, Stephens LC and Fang B. (2001). Cancer Res., 61, 3330-3338.
9. Kim GY, Mercer SE, Ewton DZ, Van Z, Jin K and Friedman E. (2002). J. Biol. Chem., 277, 29792-29802.
10. King RW, Deshaies RJ, Peters JM and Kirschner MW. (1996). Science, 274, 1652-1659.
11. Lara Jr PN, Davies AM, Mack PC, Mortenson MM, Bold RJ, Gumerlock PH and Gandara DR. (2004). Semin. Oncol., 31, 40-46.
12. Lenz HJ. (2003). Cancer Treat. Rev., 29 (Suppl 1), 41-48.
13. Li B and Dou QP. (2000). Proc. Natl. Acad. Sci. USA, 97, 3850-3855.
14. Lin YC, Brown K and Siebenlist U. (1995). Proc. Natl. Acad. Sci. USA, 92, 552-556.
15. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF and Rolfe M. (1995). Science, 269, 682-685.
16. Palombella VJ, Rando OJ, Goldberg AL and Maniatis T. (1994). Cell, 78, 773-785.
17. Pei XY, Dai Y and Grant S. (2003). Leukemia, 17, 2036-2045.
18. Schmidt C, Peng B, Li Z, Sclabas GM, Fujioka S, Niu J, Schmidt-Supprian M, Evans DB, Abbruzzese JL and Chiao PJ. (2003). Mol. Cell, 12, 1287-1300.
19. Shimizu S and Tsujimoto Y. (2000). Proc. Natl. Acad. Sci. USA, 97, 577-582.
20. Wu S, Zhu H, Gu J, Zhang L, Teraishi F, Davis JJ, Jacob DA and Fang B. (2003). Cancer Res., 64, 1110-1113.
21. Yu J, Tiwari S, Steiner P and Zhang L. (2003). Cancer Biol. Ther., 2, 694-699.